Kymera Therapeutics

Press Releases

Kymera Therapeutics Announces Leadership Transitions

Kymera Co-founder and CSO Nello Mainolfi, PhD, has been appointed President of the company as former President and CEO Laurent Audoly, PhD, has decided to pursue new entrepreneurial opportunities. Kymera Therapeutics also announced that health care financial services veteran Bruce Jacobs joins as Chief Financial Officer to direct financial operations and investor relations.

Kymera Therapeutics to Present New Preclinical Data for its First-In-Class Oral IRAK4 Degrader in MYD88-Mutant B Cell Lymphoma at the 15th International Conference on Malignant Lymphoma

Cambridge, Mass. (June 19, 2019) – Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create breakthrough medicines for patients, will present new preclinical data demonstrating its first-in-class oral IRAK4 protein degraders cause tumor regression in MYD88-mutant B cell lymphoma. Data will be shared during an oral presentation at the 15th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland on Thursday, June 20 at 5:45 PM CEST.

Vertex and Kymera Therapeutics Establish Strategic Collaboration to Discover and Develop Targeted Protein Degradation Medicines for Serious Diseases

BOSTON, MA and CAMBRIDGE, MA – May 15, 2019 – Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Kymera Therapeutics today announced that the two companies have entered into a four-year strategic research and development collaboration to advance small molecule protein degraders against multiple targets.  The collaboration will leverage Kymera’s expertise in targeted protein degradation and its proprietary PegasusTM drug discovery platform and Vertex’s scientific, clinical, and regulatory capabilities to accelerate the development of first-in-class medicines for people with serious diseases.

View All Press Releases

Blog

Targeted Protein Degradation Comes of Age (As Featured in LifeSciVC)

Translation of well validated biology into therapeutics remains one of the biggest challenges of modern drug development, in many cases due to lack of appropriate technologies to drug well credentialed biological targets. Examples in this category include driver oncogenes such as MYC, b-catenin and STAT3; catalytically active scaffolding kinases such as IRAK4 and RIPK’s or proteins whose accumulation is associated with well-established pathology such as alpha-synuclein in Parkinsons’s Disease or Tau in dementia and Alzheimer’s Disease.

Going after the “undruggable”: the STAT3 story

Targeted protein degradation (TPD) is one of the most promising and exciting therapeutic modalities today, with the potential to effectively target disease-causing proteins and signaling pathways that have long been out of reach with conventional therapeutic approaches. These are proteins that either lack catalytic activity and/or have catalytic-independent functions – targets that to date have either gone “undrugged” or have not been adequately addressed.

Protein Degradation: New Rules for Drug Discovery

Targeted protein degradation (TPD) is one of the most promising and exciting therapeutic modalities today, with the potential to effectively target disease-causing proteins and signaling pathways that have long been out of reach with conventional therapeutic approaches. These are proteins that either lack catalytic activity and/or have catalytic-independent functions – targets that to date have either gone “undrugged” or have not been adequately addressed.

View All Blog Posts